SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
CAR-T, CD19

BMS Reports Positive Topline Results From Breyanzi’s Ph3 TRANSFORM Trial in 2L DLBCL vs SoC: Will Breyanzi be the First Approved CAR-T in 2L DLBCL?

Here is a brief preview of this blast: On Thursday, June 10, BMS reported positive topline results from Breyanzi’s (CD19 CAR-T) Ph3 TRANSFORM trial in 2L DLBCL (press release). Below, Celltelligence provides insights on how Breyanzi’s potential approval timeline in 2L DLBCL compares with key competitors Kymriah (Novartis) and Yescarta (Gilead / Kite).

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.